Director

Noriyuki Kasahara, M.D., Ph.D.

Chief Scientific Officer; former Director·4D Molecular Therapeutics, Inc.

About

Appointed Chief Scientific Officer effective January 2, 2024, having joined the board as a Class I director in September 2022 (resigning from the board effective January 1, 2024). Professor and Alvera L. Kan Endowed Chair of Neurological Surgery and Radiation Oncology at UCSF with 30+ years in gene therapy.

Since 2022
Tenure 4 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Chief Scientific Officer; former Director 2022–present Current role

Related

Company 4D Molecular Therapeutics, Inc. Company hub Person David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director Person John F. Milligan, Ph.D. Director and Executive Chairman Person Jacob Chacko, M.D., MBA Director Person Susannah Gray, MBA Director Person Charles P. Theuer, M.D., Ph.D. Director Person Nancy Miller-Rich Director Person Shawn Cline Tomasello, MBA Director Person Glenn Sblendorio Director Person Kristian Humer Chief Financial Officer Person Christopher Simms Chief Commercial and Business Officer Person Scott Bizily, J.D., Ph.D. Chief Legal Officer and Corporate Secretary Person Ashoo Gupta Vice President, Finance and Controller
Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo